Table 1

Baseline patient characteristics

SLE only
n=86
LN
n=87
P value
Gender¶0.007
 Male5 (6%)17 (20%)
 Female81 (94%)70 (80%)
Age (years),§ mean (SD)42.9 (15.5)39.8 (15.7)0.20
Location¶0.32
 Metropolitan49 (57%)56 (64%)
 Regional37 (43%)31 (36%)
AASTI status¶0.64
 Non-ATSI78 (91%)77 (89%)
 ATSI8 (9%)10 (11%)
SLEDAI score*, median (IQR)2 (0–4)8 (4–16)<0.001
SLE comorbidity index*, median (IQR)0 (0–0)2 (2–5)<0.001
eGFR¶0.002
 ≥9050 (58%)35 (40%)
 6022 (26%)18 (21%)
 30–595 (6%)18 (21%)
 15–290 (0%)7 (8%)
 <159 (10%)9 (10%)
Total number of immunosuppressant agents,*† median (IQR)2.0 (1.0–2.0)3.0 (2.0–3.0)<0.001
Total number of immunosuppressant agents†¶<0.001
 010 (12%)3 (3%)
 131 (36%)7 (8%)
 230 (35%)22 (25%)
 3+15 (17%)55 (63%)
 Prednisone (n=169)¶37 (44%)72 (85%)<0.001
 Prednisone (total daily dose or equivalent, mg),* median (IQR)0.0 (0.0–5.0)5.0 (3.0–15.0)<0.001
 Hydroxychloroquine¶68 (79%)69 (79%)0.97
 Mycophenolate¶3 (3%)45 (52%)<0.001
 Cyclophosphamide‡3 (3%)26 (30%)<0.001
 Azathioprine¶9 (10%)20 (23%)0.027
 Cyclosporine¶0 (0%)3 (3%)0.25
 Methotrexate¶16 (19%)6 (7%)0.021
 Leflunomide‡3 (3%)1 (1%)0.37
 Rituximab‡0 (0%)1 (1%)1.00
 Tacrolimus‡0 (0%)5 (6%)0.059
Creatinine* (µmol/L, n=166), median (IQR)64 (52–70)78 (59–113)<0.001
Urine protein:creatinine ratio* (n=118), median (IQR)9 (3–16)84 (16–302)<0.001
Lupus duration* (years, n=165), median (IQR)6.0 (1.9–14.7)6.6 (1.7–12.6)0.98
Lupus nephritis class
 Class I1 (1%)
 Class II4 (5%)
 Class III18 (21%)
 Class IV33 (38%)
 Class V11 (13%)
 Class III, class V5 (6%)
 Class IV, class V3 (3%)
 Unknown12 (14%)
Biopsy proven
 No7 (8%)
 Yes76 (87%)
 Unknown4 (5%)
Median time from biopsy to index visit (IQR) (years, n=76)0.8 (0.1–5.9)
  • *Mann-Whitney U test.

  • †Total number of immunosuppressant agents includes prednisone.

  • ‡Fisher’s exact test.

  • §Student t-test.

  • ¶χ2 test.

  • ATSI, Aboriginal and Torres Strait Islander; eGFR, estimated glomerular filtration rate; LN, lupus nephritis; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.